Interleukin-2 in Treating Patients With Metastatic Kidney Cancer

Completed · Phase 4

Conditions studied: Kidney Cancer

In brief

RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill kidney cancer cells. PURPOSE: Phase IV trial to study the effectiveness of interleukin-2 in treating patients who have metastatic kidney cancer.

Key facts

Study ID

NCT00006864

Run by

Case Comprehensive Cancer Center

Starts

2000-07-01

Expected to finish

2007-07-01

Last updated by the study team

2014-01-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Northwestern Connecticut Oncology-Hematology Associates — Torrington, Connecticut, United States
• Ireland Cancer Center — Cleveland, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.